Cobimetinib

Worldwide Melanoma Treatment Industry to 2027 - Players Include Novartis, Pfizer, Sanofi and AstraZeneca - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 12, 2022

The "Melanoma Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Melanoma Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • These changes are increasing the incidence of melanoma patients worldwide, raising the demand for proper methods of treatment.
  • By type, cutaneous melanoma is widely spread globally caused by too much exposure to ultraviolet rays from the sun and indoor tanning.
  • Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.

Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Retrieved on: 
Thursday, July 22, 2021

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021

Retrieved on: 
Thursday, July 8, 2021

Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.
  • Exelixis is a member of the Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May

Retrieved on: 
Tuesday, April 27, 2021

Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline.

Key Points: 
  • Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline.
  • Exelixis is a member of the Standard & Poor\xe2\x80\x99s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.\nExelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.
  • MINNEBRO is a registered Japanese trademark.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210427006099/en/\n'

Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021

Retrieved on: 
Thursday, April 22, 2021

b'Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close.

Key Points: 
  • b'Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • Exelixis is a member of the Standard & Poor\xe2\x80\x99s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.\nExelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.

Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers

Retrieved on: 
Saturday, October 24, 2020

Under the agreement, AstraZeneca will sponsor and conduct this combination study and Revolution Medicines will provide clinical supply of RMC-4630.

Key Points: 
  • Under the agreement, AstraZeneca will sponsor and conduct this combination study and Revolution Medicines will provide clinical supply of RMC-4630.
  • Separately, Revolution Medicines and Amgen are collaborators in an ongoing Amgen-sponsored clinical trial studying RMC-4630 in combination with AMG 510 (soratinib), an investigational KRASG12C(OFF) inhibitor.
  • Cobimetinib is provided by Genentech for the RMC-4630-02 study under a clinical collaboration agreement with Revolution Medicines.
  • Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers.

Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

Retrieved on: 
Monday, October 12, 2020

Preliminary data to be presented at ENA 2020 will focus on safety, tolerability and pharmacokinetic findings from combination dosing regimens.

Key Points: 
  • Preliminary data to be presented at ENA 2020 will focus on safety, tolerability and pharmacokinetic findings from combination dosing regimens.
  • We are gratified that data from our ongoing combination trial of RMC-4630 and cobimetinib were selected for presentation at ENA 2020.
  • Drug combinations will likely be critical to defeating inherent drug resistance mechanisms exploited by RAS-addicted cancers, said Steve Kelsey, M.D., president of research and development at Revolution Medicines.
  • Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers.

Melanoma Research Alliance Hails FDA’s First ‘Triplet’ Combination Approval for Melanoma

Retrieved on: 
Monday, August 3, 2020

The newly approved triplet treatment is the first FDA-approved combination for metastatic melanoma that brings together immunotherapy with targeted therapies.

Key Points: 
  • The newly approved triplet treatment is the first FDA-approved combination for metastatic melanoma that brings together immunotherapy with targeted therapies.
  • In the study, the triplet combination of Tecentriq + Cotellic and Zelboraf was compared to placebo + Cotellic and Zelboraf among patients with advanced BRAF-mutant melanoma.
  • This approval demonstrates the innovative spirit within the melanoma research community, says Dr. Marc Hurlbert, MRA Chief Science Officer.
  • Due to the ongoing support of its founders, 100 percent of donations to MRA go directly to its melanoma research program.

Exelixis Announces Webcasts of Investor Conference Presentations in February

Retrieved on: 
Thursday, February 6, 2020

Guggenheim Healthcare Talks Oncology Day: Exelixis is scheduled to present at 9:00 AM EST / 6:00 AM PST on Thursday, February 13, 2020 in New York.

Key Points: 
  • Guggenheim Healthcare Talks Oncology Day: Exelixis is scheduled to present at 9:00 AM EST / 6:00 AM PST on Thursday, February 13, 2020 in New York.
  • Exelixis is a member of Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.

Exelixis Announces Webcasts of Investor Conference Presentations in December

Retrieved on: 
Tuesday, November 26, 2019

Piper Jaffray 31st Annual Healthcare Conference: Exelixis is scheduled to present at 10:00 AM EST / 7:00 AM PST on Tuesday, December 3, 2019 in New York.

Key Points: 
  • Piper Jaffray 31st Annual Healthcare Conference: Exelixis is scheduled to present at 10:00 AM EST / 7:00 AM PST on Tuesday, December 3, 2019 in New York.
  • Exelixis is a member of Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.